Introduction
============

Traumatic brain injury accounts for approximately 10 million deaths and/or hospitalizations annually in the world, and approximately 1.5 million annual emergency room visits and hospitalizations in the US ([@B74]). Young men are consistently over-represented as being at greatest risk for TBI ([@B74]). While half of all traumatic deaths in the USA are due to brain injury ([@B83]), the majority of head injuries are considered mild and often never receive medical treatment ([@B32]). Survivors of TBI are at risk for lowered life expectancy, dying at a 3⋅2 times more rapid rate than the general population ([@B11]). Survivors also face long term physical, cognitive, and psychological disorders that greatly diminish quality of life. Even so-called mild TBI without notable cell death may lead to enduring cognitive deficits ([@B100]; [@B119]). A 2007 study estimated that TBI results in \$330,827 of average lifetime costs associated with disability and lost productivity, and greatly outweighs the \$65,504 estimated costs for initial medical care and rehabilitation ([@B46]), demonstrating both the long term financial and human toll of TBI.

The development of management protocols in major trauma centers ([@B20]) has improved mortality and functional outcomes ([@B134]). Monitoring of intracranial pressure is now standard practice ([@B22]), and advanced MRI technologies help define the extent of brain injury in some cases ([@B125]). Current treatment of major TBI is primarily managed through surgical intervention by decompressive craniotomy ([@B24]) which involves the removal of skull segments to reduce intracranial pressure. Delayed decompressive craniotomy is also increasingly used for intractable intracranial hypertension ([@B121]). The craniotomy procedure is associated with considerable complications, such as hematoma, subdural hygroma, and hydrocephalus ([@B136]). At present, the pathology associated with TBI remains refractive to currently available pharmacotherapies ([@B94]) and as such represents an area of great research interest and in need of new potential targets. Effective TBI drug therapies have yet to be proven, despite promising preclinical data ([@B78]; [@B87]; [@B124]) plagued by translational problems once reaching clinical trials ([@B142]; [@B139]; [@B86]).

The many biochemical events that occur in the hours and months following TBI have yielded preclinical studies directed toward a single injury mechanism. However, an underlying premise of the present review is an important need to address the multiple targets associated with secondary injury cascades following TBI. A growing body of published scientific research indicates that the endogenous cannabinoid (endocannabinoid; eCB) system possesses several targets uniquely positioned to modulate several key secondary events associated with TBI. Here, we review the preclinical work examining the roles that the different components of the eCB system play in ameliorating pathologies associated with TBI.

The Endocannabinoid (eCB) System
================================

Originally, "Cannabinoid" was the collective name assigned to the set of naturally occurring aromatic hydrocarbon compounds in the *Cannabis sativa* plant ([@B89]). Cannabinoid now more generally refers to a much more broad set of chemicals of diverse structure whose pharmacological actions or structure closely mimic that of plant-derived cannabinoids. Three predominant categories are currently in use; plant-derived phytocannabinoids (reviewed in [@B50]), synthetically produced cannabinoids used as research ([@B152]) or recreational drugs ([@B95]), and the endogenous cannabinoids, *N*-arachidonoylethanolamine (anandamide) ([@B40]) and 2-AG ([@B88]; [@B138]).

These three broad categories of cannabinoids generally act through cannabinoid receptors, two types of which have so far been identified, CB~1~ ([@B39]) and CB~2~ ([@B98]). Both CB~1~ and CB~2~ receptors are coupled to signaling cascades predominantly through G~i/o~-coupled proteins. CB~1~ receptors mediate most of the psychomimetic effects of cannabis, its chief psychoactive constituent THC, and many other CNS active cannabinoids. These receptors are predominantly expressed on pre-synaptic axon terminals ([@B3]), are activated by endogenous cannabinoids that function as retrograde messengers, which are released from post-synaptic cells, and their activation ultimately dampens pre-synaptic neurotransmitter release ([@B80]). Acting as a neuromodulatory network, the outcome of cannabinoid receptor signaling depends on cell type and location. CB~1~ receptors are highly expressed on neurons in the central nervous system (CNS) in areas such as cerebral cortex, hippocampus, caudate-putamen ([@B58]). In contrast, CB~2~ receptors are predominantly expressed on immune cells, microglia in the CNS, and macrophages, monocytes, CD4+ and CD8+ T cells, and B cells in the periphery ([@B26]). Additionally, CB~2~ receptors are expressed on neurons, but to a much less extent than CB~1~ receptors ([@B9]). The abundant, yet heterogeneous, distribution of CB~1~ and CB~2~ receptors throughout the brain and periphery likely accounts for their ability to impact a wide variety of physiological and psychological processes (e.g., memory, anxiety, and pain perception, reviewed in [@B41]) many of which are impacted following TBI.

Another unique property of the eCB system is the functional selectivity produced by its endogenous ligands. Traditional neurotransmitter systems elicit differential activation of signaling pathways through activation of receptor subtypes by one neurotransmitter ([@B128]). However, it is the endogenous ligands of eCB receptors which produce such signaling specificity. Although several endogenous cannabinoids have been described ([@B115]; [@B30]; [@B57]) the two most studied are anandamide ([@B40]) and 2-AG ([@B88]; [@B138]). 2-AG levels are three orders of magnitude higher than those of anandamide in brain ([@B15]). Additionally, their receptor affinity ([@B113]; [@B117]) and efficacy differ, with 2-AG acting as a high efficacy agonist at CB~1~ and CB~2~ receptors, while anandamide behaves as a partial agonist ([@B60]). In addition, anandamide binds and activates TRPV1 receptors ([@B92]; [@B158]; [@B130]), whereas 2-AG also binds GABA~A~ receptors ([@B129]). As such, cannabinoid ligands differentially modulate similar physiological and pathological processes.

Distinct sets of enzymes, which regulate the biosynthesis and degradation of the eCBs and possess distinct anatomical distributions (see **Figure [1](#F1){ref-type="fig"}**), exert control over CB~1~ and CB~2~ receptor signaling. Inactivation of anandamide occurs predominantly through FAAH ([@B36], [@B35]), localized to intracellular membranes of postsynaptic somata and dendrites ([@B53]), in areas such as the neocortex, cerebellar cortex, and hippocampus ([@B44]). Inactivation of 2-AG proceeds primarily via MAGL ([@B42]; [@B18]), expressed on presynaptic axon terminals ([@B53]), and demonstrates highest expression in areas such as the thalamus, hippocampus, cortex, and cerebellum ([@B42]). The availability of pharmacological inhibitors for eCB catabolic enzymes has allowed the selective amplification of anandamide and 2-AG levels following brain injury as a key strategy to enhance eCB signaling and to investigate their potential neuroprotective effects.

![**Endocannabinoid system cell localization by CNS cell type.** Endocannabinoid functional specialization among CNS cell types is determined by the cellular compartmentalization of biosynthetic and catabolic enzymes (biosynthesis by NAPE and DAGL-α, -β, catabolism by FAAH and MAGL). Cellular level changes in eCB biosynthetic and catabolic enzymes as a result of brain injury have yet to be investigated, though morphological and molecular reactivity by cell type is well documented.](fphar-08-00069-g001){#F1}

Finally, 2-AG functions not only as a major cannabinoid receptor signaling molecule, but also serves as a major precursor for AA, and therefore plays a role in inflammatory pathways (see **Figure [2](#F2){ref-type="fig"}**). Although AA is a degradative product of both 2-AG ([@B13]) and anandamide ([@B38]), MAGL represents a rate-limiting biosynthetic enzyme of highly bioactive lipid in brain, liver, and lung ([@B103]). Historically, cPLA2 was considered to be the primary rate-limiting enzyme in AA production (reviewed in [@B23]). However, MAGL contributes ∼80% and cPLA2 ∼20% of LPS-stimulated eicosanoids in mouse brain. In contrast, cPLA2 is the dominant enzyme to control AA production in spleen ([@B103]). Therefore, MAGL and cPLA2 appear to play differential roles in AA production, and concomitantly its eicosanoid metabolites in a tissue-specific manner ([@B103]). As such, 2-AG functions not only as an endogenous CB1 and CB2 receptor ligand, but also an immunomodulator by virtue of its being a major precursor for AA, making it a versatile target for the treatment of TBI related pro-inflammatory pathologies. Understanding the biosynthesis mechanisms of eCBs may prove useful in modulating their entry into pro-inflammatory pathways. While 2-AG is known to be synthesized by DAGL-α and DAGL-β ([@B16]), the mechanisms mediating anandamide production are incompletely understood ([@B17]).

![**Enzymatic regulation of anandamide and 2-AG in normal brain, and following TBI.** 2-AG levels are approximately 1,000-fold higher than anandamide levels in brain. MAGL plays a rate-limited role in the production of AA in brain, lung, and liver ([@B102]). Arrows represent known TBI-induced changes in eCBs, catabolic and downstream enzymes, and their metabolic products (arrow size has no relation to magnitude of change).](fphar-08-00069-g002){#F2}

Traumatic Brain Injury Pathology
================================

Traumatic brain injuries are heterogeneous in their etiology, clinical presentation, severity, and pathology. The sequelae of molecular, biochemical, and physiological events that follow the application of an external mechanical force produce interacting acute and delayed pathologies, described as primary and secondary injuries. The initial insult produces an immediate mechanical disruption of brain tissue ([@B118]). This primary injury consists of contusion, blood vessel disruption and brain oedema, localized necrotic cell death, as well as diffuse axonal injury producing degeneration of cerebral white matter ([@B1]; [@B49]).

Secondary injury mechanisms are initiated within minutes, in which necrotic and apoptotic cell death in contused areas and pericontusional penumbra continue over a period of days to months ([@B116]). Neuronal disruption spills excitatory amino acids into the interstitial space, producing glutamate-mediated excitotoxicity ([@B25]). Massive influx of Ca^2+^ into cells ([@B48]) produce mitochondrial dysfunction and the release of ROS which lead to further apoptosis ([@B157]). Injury-induced activation of CNS resident glial cells, microglia, as well as recruitment of circulating inflammatory cells, e.g., macrophages, then produce secretion of inflammatory mediators, cytokines and chemokines (reviewed in [@B153]). Increased intracranial pressure leads to reductions in cerebral blood flow ([@B126]), while injury-induced breakdown of the cerebrovascular endothelium contributes to dysfunction of the BBB ([@B29]). Extracranial pathologies are also evident following TBI with pulmonary complications being the most common ([@B111]). NPE often develops early after brain injury, producing hypoxemia and further aggravating secondary brain injury ([@B21]; [@B104]). These varied and interacting disease processes highlight the necessity to address the multiple targets associated with secondary injury cascades following TBI.

While there are many types of CNS injury models \[e.g., spinal cord injury, lesion studies, focal and global ischemic injury etc. ([@B6]; [@B143])\], this review will focus primarily on the work investigating manipulations of the eCB system in preclinical models of TBI.

Pre-Clinical Evaluation of Cannabinoids to Treat TBI
====================================================

While basal anandamide and 2-AG levels differ within various structures in the CNS, levels increase on demand in response to a given stimuli \[e.g., the induction of nausea ([@B135]) or pain states ([@B33])\]. eCBs are lipid messengers not stored in synaptic vesicles (likely due to their hydrophobicity) but rather synthesized in an activity-dependent manner from membrane phospholipid precursors ([@B3]). Consequently, eCB signaling is enhanced by a stimulus-response synthesis and release mechanism.

Endocannabinoid levels increase in selected CNS tissue following neuronal damage, which may reflect a self-neuroprotective response. NMDA excitotoxicity produces elevations of anandamide in ipsilateral cortex of rats by 4-fold at 4 h and 14-fold at 24 h, but with no changes in 2-AG levels ([@B55]). Concussive head trauma in rats produces a similar pattern of findings in which modest increases of anandamide levels occur in ipsilateral cortex, and again with no change in 2-AG levels ([@B55]). This pattern was replicated by [@B140], who found a 1.5-fold increase of anandamide levels at 3 days post-TBI in ipsilateral mouse brain, and with no change in 2-AG. In contrast, [@B110] reported that TBI in mice led to increases of 2-AG in ipsilateral brain from 1 to 24 h with elevations as high as 10-fold. Thus, further research is needed to discern whether species differences, the model used to elicit neurotrauma, and/or other procedural considerations contribute to the differential elevation of these eCBs ([@B90]).

A lack of studies systematically investigating the consequences of TBI on changes in eCB levels in specific brain regions perhaps point to the difficulty in measuring changes in the volatile eCBs, prone to rapid degradation ([@B37]; [@B42]). While pharmacological and genetic manipulations of the eCB system continue to be evaluated following TBI; full characterization of how eCB biosynthetic and degradative enzymes, receptors, and endogenous ligands, their precursors and catabolic products, change as a consequence of TBI remains to be fully illuminated.

Treatment of Cellular and Molecular Pathophysiology of TBI
----------------------------------------------------------

In this section, we review preclinical studies of cannabinoids in the context of their potential to protect against cellular and molecular TBI pathology (see **Table [1](#T1){ref-type="table"}**).

###### 

Effect of cannabinoids on TBI-induced cellular and molecular pathophysiology.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound/mutant                         Dose              Species           TBI model/severity      Effect                                                          Receptor mediated   Reference
  --------------------------------------- ----------------- ----------------- ----------------------- --------------------------------------------------------------- ------------------- -----------
  **CNS cell death**                                                                                                                                                                      

  O-1966                                  5 mg/kg, i.p.     Mouse\            CCI, moderate           ↓ Neurodegeneration                                             CB~2~               [@B5]
                                                            C57BL/6                                                                                                                       

  PF3845                                  5 mg/kg, i.p.     Mouse\            CCI, severe             ↓ Lesion volume\                                                Not evaluated       [@B140]
                                                            C57BL/6                                   ↓ Neurodegeneration\                                                                
                                                                                                      → Bcl-2, Hsp70 and 72                                                               

  JZL184                                  10 mg/kg, i.p.    Mouse\            CHI, mild repetitive    ↓ Neurodegeneration                                             Not evaluated       [@B155]
                                                            C57BL/6                                                                                                                       

  WWL70                                   10 mg/kg, i.p.    Mouse\            CCI, severe             ↓ Lesion volume\                                                CB~1~\              [@B141]
                                                            C57BL/6                                   ↓ Neurodegeneration                                             CB~1~ and CB~2~     

  **Excitotoxicity**                                                                                                                                                                      

  Rimonabant                              2 mg/kg, i.p.     Rat\              Lateral FPI, severe     mGluR~5~ receptor recovery at 6 weeks (no impact on mGluR~1~)   CB~1~               [@B151]
                                                            Sprague--Dawley                                                                                                               

  2-AG                                    5 mg/kg, i.p.     Mouse\            CHI, severe             → Levels of weak antioxidants                                   Not evaluated       [@B109]
                                                            Sabra                                                                                                                         

  JZL184                                  10 mg/kg, i.p.\   Mouse\            CHI, mild repetitive\   Glutamate receptor recovery\                                    Not evaluated\      [@B155]\
                                          16 mg/kg, i.p.    C57BL/6\          Lateral FPI, mild       Injury-induced ↓ in LTP protection\                             Not evaluated       [@B84]
                                                            Rat\                                      GluA1 expression protection\                                                        
                                                            W istar                                   Injury-induced → in EPSC protection                                                 

  **Neuroinflammation**                                                                                                                                                                   

  CB^1^ -/-                               N/A               Mouse\            CHI, severe             No effect on NF-κB transactivation                              N/A                 [@B108]
                                                            C57BL/6                                                                                                                       

  CB^1^ -/- +2-AG                         N/A               Mouse\            CHI, severe             No effect on NF-κB transactivation                              N/A                 [@B108]
                                                            C57BL/6                                                                                                                       

  O-1966                                  5 mg/kg, i.p.     Mouse\            CCI, moderate           Microglial activation protection                                CB~2~               [@B5]
                                                            C57BL/6                                                                                                                       

  PF3845                                  5 mg/kg, i.p.     Mouse\            CCI, severe             ↓ COX-2 Expression\                                             Not evaluated       [@B140]
                                                            C57BL/6                                   ↓ iNos expression                                                                   

  URB597                                  0.3 mg/kg, i.p.   Rat\              Lateral FPI, mild       Microglial activation protection                                Not evaluated       [@B67]
                                                            Sprague--Dawley                                                                                                               

  2-AG                                    5 mg/kg, i.p.\    Mouse\            CHI, severe\            ↓ TNFα mRNA\                                                    Not evaluated\      [@B109]\
                                          5 mg/kg, i.p.     Sabra\            CHI, severe             ↓ IL-1β mRNA\                                                   CB~1~               [@B108]
                                                            mouse\                                    ↓ IL-6 mRNA\                                                                        
                                                            C57BL/6                                   ↓ NF-κB translocation and transactivation                                           

  JZL184                                  10 mg/kg, i.p.\   Mouse\            CHI, mild repetitive\   ↓ TNFα mRNA\                                                    Not evaluated\      [@B155]\
                                          16 mg/kg, i.p.    C57BL/6\          Lateral FPI, mild       Microglial activation protection\                               Not evaluated       [@B67]
                                                            rat\                                      Microglial activation protection                                                    
                                                            Sprague--Dawley                                                                                                               

  WWL70                                   10 mg/kg, i.p.    Mouse\            CCI, severe             ↓ COX-2 expression\                                             Not evaluated       [@B141]
                                                            C57BL/6                                   ↓ iNos expression\                                                                  
                                                                                                      M1 to M2 phenotype                                                                  

  **Cerebrovascular breakdown**                                                                                                                                                           

  URB597                                  0.3 mg/kg, i.p.   Rat\              Lateral FPI, mild       BBB integrity protection                                        Not evaluated       [@B67]
                                                            Sprague--Dawley                                                                                                               

  2-AG                                    5 mg/kg, i.p.     Mouse\            CHI, severe             BBB integrity protection                                        Not evaluated       [@B109]
                                                            Sabra                                                                                                                         

  JZL184                                  16 mg/kg, i.p.    Rat\              Lateral FPI, mild       BBB integrity protection                                        Not evaluated       [@B67]
                                                            Sprague--Dawley                                                                                                               

  WWL70                                   10 mg/kg, i.p.    Mouse\            CCI, severe             BBB integrity protection                                        Not evaluated       [@B141]
                                                            C57BL/6                                                                                                                       

  **CNS cellular structure/remodeling**                                                                                                                                                   

  \                                       4 μL              Rat\              CHI, moderate           Diurnal CB~1~ expression abolished\                                                 [@B82]
  Vehicle (saline-5% ETOH)                                  Wistar                                    → Contralateral CB~1~ and CB^2^ expression                                          

  CB^1^ -/-                               N/A               Mouse\            CHI, severe             No effect on oedema                                             N/A                 [@B108]
                                                            C57BL/6                                                                                                                       

  CB^1^ -/- +2-AG                         N/A               Mouse\            CHI, severe             No effect on oedema                                             N/A                 [@B108]
                                                            C57BL/6                                                                                                                       

  Rimonabant                              2 mg/kg, i.p.     Rat\              Lateral FPI, severe     ↓ CB~1~ Expression at 6 weeks post-TBI                          CB~1~               [@B151]
                                                            Sprague--Dawley                                                                                                               

  PF3845                                  5 mg/kg, i.p.     Mouse\            CCI, severe             ↓ APP\                                                          Not evaluated       [@B140]
                                                            C57BL/6                                   → Synaptophysin                                                                     

  2-AG                                    5 mg/kg, i.v.\    Mouse\            CHI, severe\            ↓ CA3 neuron loss\                                              \                   [@B110]\
                                          5 mg/kg, i.p.     Sabra\            CHI, severe             Oedema protection\                                              CB~1~\              [@B108]
                                                            Mouse\                                    Oedema protection                                               CB~1~               
                                                            C57BL/6                                                                                                                       

  JZL184                                  10 mg/kg, i.p.\   Mouse\            CHI, mild repetitive\   ↓ APP\                                                          Not evaluated\      [@B155]\
                                          16 mg/kg, i.p.    C57BL/6\          Lateral FPI, mild       ↓ Amyloid-β peptide\                                            Not evaluated       [@B84]
                                                            Rat\                                      ↓ TDP-43 and p-tau\                                                                 
                                                            Sprague-Dawley                            ↓ astrocyte activation                                                              

  WWL70                                   10 mg/kg, i.p.    Mouse\            CCI, severe             → CB~1~ and CB~2~ Expression                                    Not evaluated       [@B141]
                                                            C57BL/6                                                                                                                       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Drug targets; CB

2

receptor agonist (O-1966), FAAH inhibitor (PF3845), MAGL inhibitors (JZL184 and URB597), ABHD6 inhibitor (WWL70), and CB

1

receptor antagonist (Rimonabant). TBI Models; CCI (controlled cortical impact), CHI (closed head injury), and FPI (fluid percussion injury).

### CNS Cell Death

Traumatic brain injury-induced neuronal loss occurs almost immediately as necrotic cell death and continues for months following the initial insult via both necrotic and apoptotic cell death ([@B116]). From a traumatic insult, the initial contused area forms a regional primary lesion or infarct surrounding which is the pericontusional penumbra, the area immediately adjacent to the primary lesion and at risk for further neurodegeneration. The evolution of the pericontusional penumbra occurs largely due to secondary injury mechanisms and has long been considered a candidate for interventions to protect against, or salvage from, further injury ([@B149]). The investigation of cannabinoids on traumatic CNS cell death have thus far demonstrated efficacy in two areas; attenuated neurodegeneration and reduced lesion volume.

Neurodegeneration, commonly measured by reductions in the neuronal marker fluoro-jade C, has been found to be readily attenuated in mice by CB~2~ receptor agonists ([@B5]), as well as by inhibitors of FAAH ([@B140]) and MAGL ([@B155]). Additionally, FAAH inhibitors produce reductions in lesion volume, and increased production of the heat shock proteins Hsp70, known to be structurally protective, and Hsp72, a negative regulator of apoptosis ([@B140]). [@B140] also showed that FAAH inhibition increased expression of the anti-apoptotic protein Bcl-2.

Several enzymes hydrolyze 2-AG including MAGL, which accounts for an estimated 85% of its total hydrolysis, as well as ABHD6 and ABHD12, which are responsible for much of the remaining 15% ([@B18]). [@B141] found that inhibition of ABHD6 also reduced lesion volume and lowered neurodegeneration in a mouse CCI model. A CB~1~ receptor antagonist attenuated the protective effects on lesion volume, while CB~1~ and CB~2~ receptor antagonists prevented the protective effects on neurodegeneration ([@B141]).

Combined, this evidence suggests that inhibitors of eCB hydrolysis offer protection against TBI-induced cell death which involve CB~1~ and CB~2~ receptors, though the distinction between the eCBs remains to be clarified. Few studies have evaluated interactions between anandamide and 2-AG in laboratory models of TBI. One study using a model of cerebral focal ischemia found that exogenously administered anandamide and 2-AG in combination reduced infarct size in rats, but with no facilitatory effects beyond anandamide or 2-AG alone ([@B150]). Given the recent availability of dual FAAH/MAGL inhibitors ([@B76]; [@B101]), simultaneous blockade of these enzymes following TBI may further reveal some insight into the relationship between anandamide and 2-AG on TBI-induced cell death.

### Excitotoxicity

Previous efforts to attenuate the effects of excitotoxicity following brain injury focused on NMDA receptor antagonists, presumably with the understanding that the induction of depressed NMDA receptor function would counteract TBI-induced excitotoxicity. This class of drugs showed promise in laboratory animal models of TBI ([@B127]), but failed to produce long-term beneficial outcomes in clinical trials, despite some acute benefits of improved intracranial pressure and cerebral perfusion pressure ([@B71]; [@B79]). Research investigating manipulations of the eCB system on glutamatergic functioning following TBI have thus far focused primarily on 2-AG, and paradoxically, its effectiveness to protect the integrity of glutamate receptor function.

Several studies investigating the effects of cannabinoids in laboratory animal models of TBI have focused on expression changes of metabotropic (mGluRbbb, mGluR~5~), AMPA (GluA1, GluA2), and NMDA (GluN1, GluN2A, GluN2B) glutamatergic receptors. Specifically, post-injury administration of the MAGL inhibitor JZL184 reversed TBI-induced reductions of GluN2A, GluN2B, and GluA1 receptor expression, but with no impact on GluN1 or GluA2 receptors ([@B155]). The CB~1~ receptor antagonist Rimonabant did not alter injury-induced lowered expression of mGluRbbb, but surprisingly reversed reduced mGluR~5~ receptor expression 6 weeks following TBI ([@B151]). Both findings were completed 30 days post injury ([@B155]; [@B151]), suggesting long term changes in glutamatergic function following acute administration of cannabinoids post-injury. However, little overlap is found between receptor expression endpoints across papers. In an example of contradictory patterns of GluA1 expression after injury, GluA1 expression was reduced in a study that subjected mice to a daily mild CHI on three consecutive days ([@B155]), and was increased in rats subjected to a single lateral fluid percussion brain injury ([@B84]). In these studies, MAGL inhibition ameliorated both the reduced ([@B155]) and increased ([@B84]) GluA1 expression. As discussed above (see Pre-Clinical Evaluation of Cannabinoids to Treat TBI), systematic investigation of species (mice vs. rat), brain injury model, number of injuries, and other experimental variables are needed to understand the consequences of brain injury on glutamate receptor changes.

Endocannabinoids are known to depress glutamate release from pre-synaptic terminals, and in particular, 2-AG has been explored in its ability to influence the functioning of electrochemical neurotransmission. MAGL inhibition has been found to protect against injury-induced increases in frequency and amplitude of EPSC in pyramidal neurons at the site of injury ([@B84]), which may suggest changes in pre-synaptic transmitter release or post-synaptic strength ([@B156]). MAGL inhibition has also protected against injury-induced LTP impairments at hippocampal CA3--CA1 synapses ([@B155]), implicating the restoration of glutamate receptor function in protection against TBI-induced memory impairments.

Finally, the excitotoxicity resulting from TBI is part of the sequelae of events that lead to release of damaging ROS. Antioxidants are known to prevent oxidation of free radicals and thus protects against the cellular damage in response to sudden ROS elevation. eCBs have been linked to the neuroprotective production of antioxidants as the administration of exogenous 2-AG following injury has been found to increase levels of antioxidants ([@B109]).

Combined, these data suggest that MAGL represents a promising target to reduce the damaging effects of injury-induced excitotoxicity through complimentary molecular pathways.

### Neuroinflammation

Hydrolytic enzymes of anandamide and 2-AG produce a shared metabolic product in the formation of free AA, the major substrate of the biosynthetic enzymes of pro-inflammatory eicosanoids ([@B103]). Therefore, eCB oxidation not only produces inactivation at cannabinoid receptors, but also leads to the production of bioactive lipids involved in inflammatory responses during the early stages of injury. Manipulations of the eCB system have proved effective in downregulating inflammation in many experimental models, such as inflammatory pain ([@B2]), and multiple sclerosis ([@B93]). The use of cannabinoids following TBI have thus far been linked to two predominant features of inflammation; decreased inflammatory cell activation, and decreases in pro-inflammatory cytokine production.

Pro-inflammatory activated microglia are known to exacerbate TBI-induced neuroinflammation ([@B69]). Thus, decreasing TBI-inductions of inflammatory cell activation is an attractive treatment strategy. MAGL inhibition protects against TBI-induced microglial activation ([@B155]; [@B67]), while ABHD6 inhibition promotes microglia/macrophage shift from a pro-inflammatory M1 to an anti-inflammatory M2 phenotype ([@B141]). A parsimonious explanation for these findings is that prevention of 2-AG hydrolysis leads to reduced levels of AA and concomitant reductions of pro-inflammatory mediators. Given the contribution of 2-AG catabolism to eicosanoid production, it is unsurprising that several studies have reported eCBs as demonstrating pro-inflammatory roles, some examples of which include models of nephropathy ([@B96]), cardiomyopathy ([@B97]), and experimental dermatitis ([@B106]). Most of such pro-inflammatory effects are attributed to 2-AG and not anandamide, likely due to its considerable abundance over anandamide. However, FAAH inhibition, similarly has been found to protect against TBI-induced microglial activation ([@B67]), as too has activation of CB~2~ receptors ([@B5]). Thus, a need exists to disentangle the potential contributions of 2-AG to pro-inflammatory processes from its role as a substrate for AA production, versus anti-inflammatory effects through cannabinoid receptors, following TBI.

Inhibition of eCB degradative enzymes has also produced decreases in TBI-induced pro-inflammatory mediators. Reductions in the expression of inducible enzymes that trigger eicosanoid production following brain injury, COX-2 enzyme (which converts free AA to prostaglandins) and iNos (which produces the free radical nitric oxide in response to cytokine signaling), are seen in response to ABHD6 inhibition ([@B141]) and FAAH inhibition ([@B140]). Reductions in TBI-induced pro-inflammatory cytokine mRNA (Il-1β, TNFα, and IL-6) have also been found following treatment with exogenous 2-AG ([@B109]). These findings seem counter-intuitive given the possibility of the rapid oxidation of 2-AG and its consequent contribution to eicosanoid production. However, exogenous 2-AG has also been shown to ameliorate TBI-induced transactivation of the nuclear factor NF-kB (linked to cytokine production) in wild type mice, but not in CB~1~ knockout mice, suggesting that CB~1~ receptors mediate the protective effects of exogenous 2-AG ([@B108]).

### Cerebrovascular Breakdown

The blood vessels which carry oxygen rich blood to the brain are lined by endothelial cells as well as astrocytes. These cells, combined with specific transport proteins and enzymes, strictly regulate movement between the general circulation and CNS extracellular fluid, and are collectively known as the BBB. TBI has been well documented in producing cerebral blood flow pathology ([@B68]) as well as interfering with BBB integrity ([@B12]). Given that cannabinoids are known to exert vascular effects, producing vasodilation as well as hypotension (reviewed in [@B61]), their manipulation may hold promise as protectants against cerebrovascular damage. Below, we review studies examining the effects of cannabinoids on TBI-induced disruption of BBB integrity.

Exogenous administration of 2-AG ([@B109]), as well as MAGL inhibition ([@B67]), and ABHD6 inhibition ([@B141]) administered post-injury protect against BBB breakdown. However, [@B109] found that the expression of proteolytic enzymes implicated in BBB breakdown were unaffected by exogenous 2-AG post-injury. These enzymes include matrix metallopeptidase-9 (MMP9) involved in extracellular matrix degradation, and tumor necrosis factor-α-converting enzyme (TACE), which cleaves membrane-bound proteins. The mechanism by which 2-AG acts as a protectant of BBB integrity following traumatic insult is yet to be resolved.

One study found that post-surgery administration of a FAAH inhibitor protected against BBB breakdown ([@B67]), suggesting that anandamide and/or other substrates of this enzyme play a protective role. While the mechanism underlying the structural protection of the BBB was not explored following TBI, anandamide has been found to decrease BBB permeability in a model of ischaemic stroke by transient receptor potential cation channel, subfamily V, member 1 (TRPV1) ([@B62]). Given that activation of TRPV1 receptors disrupts BBB integrity ([@B64]), it is possible that anandamide, as a partial agonist at TRPV1 channels ([@B113]), maybe be acting as a functional antagonist against a high efficacy endogenous agonist to produce its structurally protective effects of the cerebral microvascular endothelium. The exploration of how anandamide may be exerting its protective effects of BBB integrity may yet yield further novel targets for the treatment of TBI.

In cerebral circulation, CB~1~ receptor activation produces vasodilation. Indeed, the CB~1~ receptor antagonist rimonabant inhibited hypotension induced by endotoxin shock and hemorrhagic shock, as well as increasing survival ([@B146]). Though cannabinoids are yet to be explored in the context of TBI-induced changes in cerebral blood flow, CB~1~ receptor antagonism may prove to be a potential target for the treatment of TBI-induced hypotension.

### Cell Structure/Remodeling

The key biological idea that structure dictates function also holds true for the neurophysiology of TBI. The shearing and tearing forces of TBI and subsequent secondary injury cascades produce changes in cell architecture, extracellular matrices, and the balance of fluid homeostasis, that impair neuronal function often both in a focal and/or diffuse manner throughout the brain ([@B49]). The use of cannabinoids has thus far been linked to protection against several of the CNS structural changes associated with TBI, with 2-AG being the most frequently studied eCB in this area.

While a traumatic insult can result in the rapid onset of cerebral oedema, exogenously administered 2-AG protects against TBI-induced oedema ([@B110], [@B108]). The observation that no such oedema protection was found following 2-AG administration in CB~1~ receptor^-/-^ mice ([@B108]) suggests that this protection requires CB~1~ receptor activation. Changes in protein physiology have also been found to occur following TBI. Specifically, the presence of protein aggregates such as amyloid-β plaques ([@B66]), p-tau ([@B52]), and TDP-43 ([@B131]), have been found within hours following TBI. These proteins are thought to accumulate from damaged axons and as a result of a disturbed balance between genesis and catabolism ([@B66]). MAGL inhibitors decrease amyloid-β protein and its precursor molecule APP, as well as p-tau and TDP-43 ([@B155]). MAGL inhibition also decreases astrocyte activation ([@B84]), while exogenous 2-AG following TBI reduces hippocampal CA-3 neuron loss ([@B110]). These consistent protective effects of 2-AG across varied TBI-related structural pathologies point to its important role in maintaining cell structure and promoting remodeling.

Protective roles played by anandamide in injury-induced structural changes are yet to be ascertained. Though FAAH inhibition decreases APP expression post-injury, as well as increases synaptophysin ([@B140]), a synaptic vesicle protein whose elimination impairs object recognition and spatial learning in mice ([@B123]). Furthermore, eCBs may not be working alone to offer protection from TBI-induced structural impairments. For example, estradiol decreased the number of TBI-induced immunoreactive astrocytes, which was inhibited by CB~1~ and CB~2~ receptor antagonists, while also increasing cerebral cortex mRNA levels of CB~2~ receptors ([@B77]). These findings suggest that the regulatory activity of the eCB receptors in response to TBI may be mediated by endocrine as well as paracrine signaling mechanisms.

Traumatic brain injury is well described to increase CB~1~ and CB~2~ receptor expression, which includes disruption of diurnal rhythms of CB~1~ receptor expression ([@B82]). Post-injury treatment with a CB~1~ receptor antagonist reduces CB~1~ receptor expression at 6 weeks following injury ([@B151]), whereas ABHD6 inhibition produces increased CB~1~ and CB~2~ receptor expression ([@B141]). As such, TBI-induced increases in cannabinoid receptor expression are perhaps facilitated by 2-AG.

### Neurogenic Pulmonary Oedema

Pulmonary complications are reported in 20--25% of TBI patients ([@B63]), and its severity is related to brain injury magnitude ([@B4]). The exact CNS circuits involved in NPE have yet to be identified, though a sudden rise in intracranial pressure, rapid sympathetic surge, increased systemic vascular resistance and increase in hydrostatic pressure in the pulmonary vasculature, as well as release of pro-inflammatory mediators may all contribute to interstitial pulmonary oedema formation ([@B21]). NPE rapidly occurs within hours of TBI onset in clinical populations ([@B4]), and within minutes in animal models ([@B8]), producing CNS hypoxia ([@B104]) which further contributes to secondary injury. NPE is a much needed area of interest in the study of TBI.

While at the present time there are no studies evaluating the contributions of, or protection by, the eCB system to NPE following TBI, this may prove an interesting area of future investigation. Specifically, the lung possesses a basal tone of 2-AG ([@B10]; [@B102]), and recently it has been shown that resident lung macrophages express major components of the eCB system, CB~1~ and CB~2~ receptors as well as anandamide and 2-AG ([@B132]). Furthermore, MAGL inhibition has already been found to be protective against LPS-induced acute lung injury in mice, and attenuated with CB~1~ and CB~2~ receptor antagonists ([@B34]).

Treatment of Behavioral Deficits of TBI
---------------------------------------

The heterogeneous clinical presentation of TBI pathology in populations of survivors is reminiscent of its cellular and molecular pathophysiology described above. TBI patients report changes in mental health (depression, irritability, anxiety, and personality changes), sleep disturbance, post-traumatic headaches, persistent fatigue, epilepsy, learning and memory deficits (manifested also as impairments in attention and processing speed \[[@B145]\]), and balance disorders ([@B133]). Most frequently investigated measures in the pre-clinical TBI literature include neurological motor, and learning and memory impairments, leaving a wide breadth of TBI clinical effects yet to be studied. Once again, components of the eCB system may become active to compensate for TBI symptomology given what is currently known of its regulatory effects within these areas, two examples being pain, and anxiety and depression ([@B31]).

In this section, we review what is currently known of cannabinoids in the context of their ability to alter post-traumatic animal behavior (see **Table [2](#T2){ref-type="table"}**).

###### 

Effect of cannabinoids on TBI-induced behavioral impairments.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound/mutant                   Dose                   Species            TBI model/severity      Effect                                           Receptor mediated          Reference
  --------------------------------- ---------------------- ------------------ ----------------------- ------------------------------------------------ -------------------------- -----------
  **Learning and memory**                                                                                                                                                         

  PF3845                            5 mg/kg, i.p.          Mouse\             CCI, severe             Y-maze deficit protection                        CB~1~\                     [@B140]
                                                           C57BL/6                                                                                     Partial CB~2~              

  JZL184                            10 mg/kg, i.p.         Mouse\             CHI, mild repetitive    MWM deficit reduction                            Not evaluated              [@B155]
                                                           C57BL/6                                                                                                                

  WWL70                             10 mg/kg, i.p.         Mouse\             CCI, severe             Y-maze deficit protection\                       Not evaluated              [@B141]
                                                           C57BL/6                                    No impact on MWM deficit                                                    

  **Neurological motor deficits**                                                                                                                                                 

  CB^1^ -/-                         N/A                    Mouse\             CHI, severe             Impaired NSS score                               CB~1~                      [@B108]
                                                           C57BL/6                                                                                                                

  CB^1^ -/- +2-AG                   N/A                    Mouse\             CHI, severe             Impaired NSS score                               CB~1~                      [@B108]
                                                           C57BL/6                                                                                                                

  O-1966                            5 mg/kg, i.p.          Mouse\             CCI, moderate           Rotarod deficit protection                       Not evaluated              [@B5]
                                                           C57BL/6                                                                                                                

  Anandamide                        1.25 μg/4 μL, ICV      Rat\               CHI, moderate           Improved NSS score                               Not evaluated              [@B82]
                                                           Wistar                                                                                                                 

  PF3845                            5 and 10 mg/kg, i.p.   Mouse\             CCI, severe             Beam-walk deficit protection                     Partial CB~1~\             [@B140]
                                                           C57BL/6                                                                                     CB~2~                      

  URB597                            0.3 mg/kg, i.p.        Rat\               Lateral FPI, mild       No impact on NSS or NBS                          Not evaluated              [@B67]
                                                           Sprague--Dawley                                                                                                        

  2-AG                              5 mg/kg, i.v.          Mouse\             CHI, severe             Improved NSS score                               Not evaluated              [@B110]
                                                           Sabra                                                                                                                  

  2-AG + 2-PG + 2-LG                1 mg/kg, i.v.          Mouse\             CHI, severe             Improved NSS score                               Not evaluated              [@B110]
                                                           Sabra                                                                                                                  

  JZL184                            10 mg/kg, i.p.\        Mouse\             CHI, mild repetitive\   Improved NSS score\                              Not evaluated\             [@B155]\
                                    16 mg/kg, i.p.\        C57BL/6\           Lateral FPI, mild\      Improved NSS and NBS score, out to 1 d\          Not evaluated\             [@B67]\
                                    16 mg/kg, i.p.         rat\               Lateral FPI, mild       Improved NSS and NBS score, out to 14 d          Not evaluated              [@B84]
                                                           Sprague--Dawley\                                                                                                       
                                                           Rat\                                                                                                                   
                                                           Sprague--Dawley                                                                                                        

  WWL70                             10 mg/kg, i.p.         Mouse\             CCI, severe             Improved NSS score\                              Not evaluated              [@B141]
                                                           C57BL/6                                    Rotarod deficit protection                                                  

  **Anxiety-like behavior**                                                                                                                                                       

  \                                 5 and 10 mg/kg, i.p.   Mouse\             CCI, severe             Zero-maze anxiety-like profile protection        No CB~1~, CB~2~ reversal   [@B140]
  PF3845                                                   C57BL/6                                                                                                                

  **Post-traumatic seizures**                                                                                                                                                     

  \                                 2 mg/kg, i.p.          Rat\               Lateral FPI, severe     Protective against seizure threshold deficits\   CB~1~                      [@B151]
  Rimonabant                                               Sprague--Dawley                            Lowered seizure mortality                                                   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Drug targets; CB

2

receptor agonist (O-1966), FAAH inhibitor (PF3845), MAGL inhibitors (JZL184 and URB597), ABHD6 inhibitor (WWL70), and CB

1

receptor antagonist (Rimonabant). TBI Model definitions; CCI (controlled cortical impact), CHI (closed head injury), and FPI (fluid percussion injury).

### Learning and Memory

Learning and memory impairments are among the most frequently reported symptoms following TBI, and are slow to recover with deficiencies reported 10 years later ([@B154]). The eCB system has been shown to play a well-documented role in memory regulation (reviewed in [@B91]), and as such its manipulation holds considerable promise to address such a profound consequence of TBI.

Inhibition of the eCB hydrolytic enzymes FAAH ([@B140]), MAGL ([@B155]), and ABHD6 ([@B141]) have been shown to protect against TBI-induced memory impairments, suggesting that anandamide and 2-AG elevation post-TBI may offer protection from TBI-induced learning and memory deficits. The protective effects of 2-AG appear to be task specific, with ABHD6 inhibition showing learning and memory protection in a Y-maze task, but not a Morris water maze task. To date, only a Y-maze task has been used to evaluate the memory protective effects of FAAH inhibition, and this task-specific effect did not occur with a MAGL inhibitor. Mice are a well-used pre-clinical model organism to study the memory effects of TBI; however, they are known to perform behavioral tasks more readily, and with less error, when the task does not rely on aversive motivation ([@B137]). This attribute of mice may, in some part, contribute to the task-related differences seen between the Y-maze task (which uses exploratory behaviors associated with novelty) and the aversively motivated escape behavior necessary in the Morris water maze. Regardless, in clinical populations the most common memory process vulnerable to TBI involves difficulties applying active or effortful strategy's in the learning or retrieval process ([@B145]). Moving forward, the use of behavioral tasks able to selectively assess such frontal lobe-type memory impairments might improve the translational capacity of eCB TBI pre-clinical assessments (one such example being the Morris water maze Reversal Task, which evaluates cognitive flexibility).

### Neurological Motor

Traumatic brain injury-induced neurological motor impairments currently represent the most frequently studied behavioral outcome measure in the TBI-cannabinoid literature. In clinical populations, neurological motor impairments seen as a result of TBI show spontaneous improvement over time, but one third of patients continue to experience neuromotor abnormalities 2 years after injury ([@B147]). A variety of eCB system manipulations have thus far been found to be protective against the neurological motor deficits associated with murine models of TBI.

Both 2-AG and anandamide elevation provide protection against TBI-induced neurological motor deficits. MAGL inhibitors ([@B155]; [@B67]; [@B84]), ABHD6 inhibitors ([@B141]), and exogenous 2-AG administration ([@B110]), improve NSS in laboratory animal models of TBI. Moreover, ABHD6 inhibition also protects against TBI-induced rotarod deficits ([@B141]). Administration of exogenous 2-AG did not enhance NSS scores in CB~1~ receptor knockout mice subjected to TBI ([@B108]), suggesting a CB~1~ receptor mechanism of action. FAAH inhibition has produced mixed findings in neurological motor tests, such as beam-walk deficit protection ([@B140]) but no improvement on TBI-induced NSS deficits ([@B67]). In support of anandamide being protective against TBI-induced motor deficits, exogenous anandamide has also produced improved NSS performance ([@B82]). Full reversal, and partial reversal, of FAAH inhibitor mediated beam-walk deficit protection by respective CB~2~ and CB~1~ receptor antagonists ([@B140]), suggest a role of both of these receptors in anandamide's neuromotor deficit sparing effects. The involvement of the CB~2~ receptor is further supported by rotarod deficit protection from a CB~2~ receptor agonist ([@B5]).

The role of entourage effects has also been evaluated in the area of TBI-induced neurological motor impairments. Co-release of endogenous fatty acid derivatives can potentiate 2-AG signaling, termed an entourage effect ([@B14]; [@B73]; [@B75]). Administration of 2-AG with two related lipids that do not bind cannabinoid receptors, 2-LG and 2-PG, enhances recovery from TBI-induced NSS deficits ([@B110]). Given FAAH is responsible for the degradation of various fatty acid amides in addition to anandamide ([@B19]), its various substrates may work in concert to ameliorate pathologies related to TBI. Thus any inferences drawn about anandamide through the use of FAAH inhibition needs to consider contributions of non-cannabinoid fatty acid amides.

### Anxiety and Post-Traumatic Seizures

The signs of post-traumatic anxiety have been difficult to replicate in murine models of TBI ([@B144]). Also, as there is a limited number of studies evaluating eCBs in this area, no definitive conclusions can be made. Thus far, only FAAH inhibition has been explored to address post-traumatic anxiety, and was found to protect against TBI-induced increases in anxiety-like behavior in mice ([@B140]). This protection in the zero maze was unaffected by either CB~1~ or CB~2~ receptor antagonists, suggesting that these receptors are dispensable. Modeling post-traumatic epilepsy is time consuming and faces other challenges such as a low percentage of animals that develop epilepsy ([@B85]), however, recent models that produce consistent replication of spontaneous seizure activity following a TBI are available ([@B114]). Contrary to preclinical research demonstrating that the eCB system plays a protective roles against seizures ([@B148]; [@B81]), a CB~1~ receptor antagonist has protected against injury-induced seizure threshold deficits as well as lowered seizure mortality ([@B151]), potentially through the disinhibition of GABAergic terminals.

This nascent body of data, suggests that eCB manipulations hold promise to treat injury-induced clinical symptoms outside of the more popular areas of learning and memory and neurological motor impairments.

Primary Phytocannabinoids and Traumatic Brain Injury
====================================================

Although currently well over one hundred phytocannabinoids have been elucidated from the *Cannabis sativa* plant ([@B45]), the most extensively studied of these are THC and cannabidiol (CBD). The investigation of phytocannabinoids on TBI pathology not only holds topical relevance, but also but also holds promise as potential treatment for TBI and other disorders.

Without exception, all of the experimental work reviewed and listed in **Tables [1](#T1){ref-type="table"}** and **[2](#T2){ref-type="table"}** have used post-injury drug administration times ranging from 15 min to several days, clearly an attempt to simulate clinical intervention timing possibilities. However, clinical and pre-clinical findings provide evidence suggesting that the primary psychoactive constituent of *Cannabis sativa*, THC, is neuroprotective when administered prior to a traumatic insult. In a 3 year retrospective study of patients who had sustained a TBI, urine toxicology screen results showed decreased mortality in individuals with a positive THC screen ([@B99]). In two mouse models of CNS injury that yield cognitive deficits, pentylenetetrazole (an excitotoxic agent) and carbon monoxide induced hypoxic injury, prior administration of THC provided impairment protection ([@B7]). Curiously, an extraordinarily a low dose of THC (i.e., 0.002 mg.kg^-1^) reduced injury-induced cognitive deficits in mice ([@B7]). The authors explained this effect through the known biphasic effects of THC producing analgesia, acute hypothermia, and decreased locomotion at high doses (10 mg.kg^-1^), and producing hyperalgesia, hyperthermia, and increased locomotion at a low dose (0.002 mg.kg^-1^) (reviewed in [@B122]). Such low dose effects of THC have been found to potentiate calcium entry into cells *in vitro* ([@B107]), increasing glutamate release, and thus may be mildly neurotoxic. Therefore, [@B7] hypothesized that low dose THC pre-treatment produced a pre-conditioning effect, where a mildly noxious stimulus becomes protective against a more severe subsequent insult, an effect known to occur in cardiology ([@B43]) as well as cerebral ischaemia ([@B70]). Moreover, the molecular signaling cascades behind cardiac and cerebral ischaemia preconditioning include activation of ERK and Akt ([@B43]; [@B51]), also shown to mediate the protective effects of ABHDB ([@B141]) and MAGL ([@B84]) inhibition following TBI.

Even though 80--90% of THC is excreted from individuals within 5 days of administration, the remaining slow release of lipophilic THC from lipid-storage compartments result in its long terminal half-life in plasma ([@B65]). As such, individuals may experience very low plasma THC concentrations for prolonged periods after each application. Although the clinical study of TBI-induced mortality reported no data to quantify levels of THC in the THC positive individuals, the low dose THC in CNS injured mice may mimic the pharmacokinetics of THC in humans. This presumed prolonged exposure of THC due to its pharmacokinetics, as well as other potentially neuroprotective cannabinoids, such as CBD ([@B112]), may be responsible for the survival effects found in cannabis-exposed TBI patients. A finding of increased clinical relevance, is that post-conditioning (when the mildly noxious stimulus is applied after the insult) with low dose THC also produced cognitive sparing effects in mice ([@B7]). These findings, however, remain controversial, and are yet to be replicated in animal models of TBI.

The phytocannabinoid CBD, currently being investigated in clinical trials for its seizure reduction potential in Tuberous Sclerosis Complex ([@B54]), has known anti-inflammatory properties. Although CBD does not bind CB~1~ and CB~2~ receptors, it activates the g-protein coupled receptor GPR55 ([@B120]), inhibits nucleoside transporter 1 ([@B27]), inhibits sodium channels ([@B59]), and produces increased extracellular adenosine concentrations that consequently downregulate inflammatory cells through the adenosine A~2A~ receptor ([@B105]; [@B56]). While there are no studies at present which have investigated the anti-inflammatory effects of CBD following TBI, CBD has reduced FosB expression following cryogenic spinal cord injury ([@B72]), and lowered iNos expression in a mouse model of tauopathy ([@B28]). As such CBD may be a promising future avenue of investigation in the study of neuroinflammation in response to brain injury.

Concluding Remarks and Future Directions
========================================

The eCB system, through release of its endogenous ligands or by changes in cannabinoid receptor constitutive activity, possesses promise in the treatment of diverse TBI pathology. An important step forward in understanding the role that the eCB system plays in TBI pathology includes not only the full characterization of ligands targeting cannabinoid receptors and eCB regulating enzymes, but also changes in cannabinoid receptors, eCB levels, and eCB regulating enzymes as a consequence of TBI. Another future area of therapeutic interest is non-CB~1~/CB~2~ receptor targets, such as TRPV1 receptors, and their potential contribution to the protective effects following TBI. Furthermore, alternative activation of CB~1~/CB~2~ receptors, such as potential entourage effects from other fatty acid derivatives, antagonism, or allosteric modulation, might impact functional selectivity and thus TBI-related outcomes also warrants further investigation. So too do the plant-derived phytocannabinoids represent an understudied yet promising group of compounds given the neuroprotective results obtained from other types of CNS injury. In particular, CBD as well as other phytocannabinoids which do not bind cannabinoid receptors, represent promising molecules to treat TBI.

To date, the only reported cannabinoid to be specifically evaluated for the treatment of TBI in patient populations is Dexanabinol, also known as HU211. While HU211 showed promise in animal models of TBI ([@B127]), it failed to produce long term patient outcomes in one clinical trial despite some acute benefits ([@B71]), and in a second study showed no short or long term benefits ([@B79]). Although HU211 has been described as a cannabinoid by virtue that it is an enantiomer of the potent synthetic cannabinoid agonist HU210, it does not bind or activate cannabinoid receptors. Instead, HU211acts as a non-competitive NMDA receptor antagonist ([@B47]). This therefore brings to light an important consideration of the classification of cannabinoids.

One consistently overlooked area across the study of TBI is the evaluation of the central penetration of systemically administered drugs. Pharmacological treatments will need to be assessed for their ability to cross the BBB. Also, it should be noted that TBI rapidly disrupts the BBB and lasts for three days post-injury ([@B12]). Furthermore, given the often biphasic nature of cannabinoid drugs, it is critical to move away from single dose pharmacology to full dose-response assessments, which may yield an increased understanding of the mechanism and potential of cannabinoids to treat TBI. Overall, the abundant and growing pre-clinical research suggests that the eCB system possesses many promising targets for new and existing drugs that may ameliorate diverse TBI pathology.
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2-AG

:   2-arachidonyl glycerol

2-LG

:   2-linoleoyl-glycerol

2-PG

:   2-palmitoyl-glycerol

AA

:   arachidonic acid

ABHD6

:   α/β-hydrolase domain-6

ABHD12

:   α/β-hydrolase domain-12

AEA

:   anandamide

APP

:   amyloid precursor protein

BBB

:   blood brain barrier

CCI

:   controlled cortical impact model of TBI

CDTA

:   calcium-dependent transacylase enzyme

CHI

:   closed head injury model of TBI

COX-2

:   cyclooxygenase-2

cPLA2

:   cytosolic phospholipase A2

DAGL-α

:   diacylglycerol lipase-α

DAGL-β

:   diacylglycerol lipase-β

eCB

:   endocannabinoid

EPSC

:   excitatory post-synaptic current

FAAH

:   fatty acid amide hydrolase

FPI

:   fluid percussion injury model of TBI

LTP

:   long term potentiation

MAGL

:   monoacylglycerol lipase

NArPE

:   N-arachidonoyl phosphatidylethanolamine

NBS

:   neurological behavioral score

NMDA

:   N-methyl-[D]{.smallcaps}-aspartate

NPE

:   neurogenic pulmonary oedema

NSS

:   neurological severity score

PLA2

:   phospholipase A2 enzyme

PLC

:   phospholipase C enzyme

p-tau

:   hyperphosphorylated tau

ROS

:   reactive oxygen species

TBI

:   traumatic brain injury

TDP-43

:   TAR DNA-binding protein

THC

:   Δ^9^-tetrahydrocannabinol
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